Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management.
about
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesEarly invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent eraDebate: Unstable angina - When should we intervene?Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent eraA population-based evaluation of the thrombolysis in myocardial infarction risk score for unstable angina and non-ST elevation myocardial infarctionPlatelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarctionMagnitude and consequences of undertreatment of high-risk patients with non-ST segment elevation acute coronary syndromes: insights from the DESCARTES RegistryGap between guidelines and management of patients with acute coronary syndrome without persistent ST elevation. Finnish prospective follow-up surveyContemporary management of acute coronary syndromeClopidogrel: an updated and comprehensive reviewGuidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of CardiologyPharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplastyAnticoagulation in the management of non-ST-segment elevation acute coronary syndrome.Acute coronary syndromes: diagnosis and management, part IUse of glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST-elevation myocardial infarction.Prospective audit of incidence of prognostically important myocardial damage in patients discharged from emergency departmentNew advances in the management of acute coronary syndromes: 1. Matching treatment to risk.Management of acute coronary syndromesTroponin: the biomarker of choice for the detection of cardiac injuryGuideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and EvaluatiRisks and benefits of glycoprotein IIb/IIIa antagonists in acute coronary syndrome.Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.Circulating high sensitivity troponin T in severe sepsis and septic shock: distribution, associated factors, and relation to outcome.Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials.Multicentre evaluation of the diagnostic value of cardiac troponin T, CK-MB mass, and myoglobin for assessing patients with suspected acute coronary syndromes in routine clinical practiceAssociations between ST depression, four year mortality, and in-hospital revascularisation in unselected patients with non-ST elevation acute coronary syndromes.FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease.Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney diseaseHigh sensitivity C-reactive protein in clinical practice.Tirofiban in acute coronary syndromes.Implications of the new definition of myocardial infarction.Biomarkers in acute coronary syndromes and their role in diabetic patients.Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm.The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients.Present and future biochemical markers for detection of acute coronary syndrome.Biomarkers in Acute Coronary Syndrome.Management of acute coronary syndrome.Intracoronary abciximab in STEMI using local drug delivery catheter - single center experience.
P2860
Q24202522-945E8EB9-D6F4-4C9E-B2B5-C2C955320756Q24202999-BB4AE301-F1CB-4F28-BEEE-DF9E99302BB8Q24235385-4E94E87A-BB6A-4DBD-BF0B-A4C0F992459BQ24236794-30E23284-D5E7-4034-8259-FFF6627C813FQ24792327-81D861C5-33E9-414E-8B09-0D81788C2229Q26471900-C07235E3-7033-4563-BB3B-150AC324CBD1Q28167379-F2DEFC12-874E-4AEB-B370-3909D3ECE238Q28191096-AAFD61FE-2240-4B24-8939-78EFCB4D1E54Q28196868-6EAEC6F2-CD16-47E5-AC0E-01165F160A7CQ28209040-42F4639F-7BC2-486D-B066-2AD3D487451CQ28212068-CE741C97-91F7-4217-8EAD-BDFE433CCB76Q28219411-CBC505E8-9101-4DFB-81FA-9E58C60EB576Q28239975-824C670B-E6D5-4816-98D2-78581821B18FQ28360267-96D6FFF7-4BBC-4F2C-AC68-F5C73086B1BCQ30402038-A2F9E2D0-00FD-40FE-81BD-B8B0AF08C477Q30490718-5299A137-F1A4-496A-BBB0-25943CBB277AQ33369310-559D781E-2634-47B8-ACD1-722EE8F61DC0Q33948859-4A4F968F-C47A-4F7A-BCFF-A36A93E13BB7Q33955730-528FCCD2-4B1C-438F-8143-0027F2C71121Q33974144-475B2C66-284C-4FC0-849F-6EBFCFEE8C75Q34117708-182188FA-99A0-4328-98CA-76B723E882AEQ34130613-8EC98750-B1E6-4493-AB04-5A2CD789E858Q34219090-34C5FBBF-8ED6-435A-8C92-6DD3543A0A0EQ34445660-B61D523C-193F-46F7-BC9C-A12A59AE7F1AQ34486797-96963C02-4485-4114-B990-EB42608C61EFQ34712338-5DC4A9B8-372D-41C5-9453-08BE11945937Q35580971-B29793D8-7A87-4E6F-A4CD-27C86026842CQ35581080-04F4130A-9F55-4BBE-B1AF-33ECAB419964Q35584557-D2EC9A2E-A4C1-4010-970C-80CC5BEBB098Q36021782-58B7FCBF-B69F-4C07-A591-00F2857F5D73Q36077858-A9E6A395-6709-454E-BC73-F39D381B177FQ36107187-7D1F4D0B-3707-4C63-B82A-87A4E9E520FDQ36249521-CA668B3A-6668-420B-A1E0-BE9D98D39DA6Q36333917-EB024547-BE2C-4DEB-A518-C32792CBEF17Q36519924-E3024915-1673-4AF0-AFB0-F5FBA710B2E1Q36614135-DBCDAD7B-07D2-4231-85C5-7D5107E2FC31Q36624223-4B6F6E55-419B-4841-867C-A9F0202F590CQ37207294-7743414F-46E5-4375-A6A4-3B7266F8E7F7Q37223676-3867DF81-410B-4FF6-8C33-A2BCEF336F9AQ37387704-DE7DBFEF-24DE-4851-82EB-4BD2DE6FD353
P2860
Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Troponin concentrations for st ...... Ischemic Syndrome Management.
@en
Troponin concentrations for st ...... Ischemic Syndrome Management.
@nl
type
label
Troponin concentrations for st ...... Ischemic Syndrome Management.
@en
Troponin concentrations for st ...... Ischemic Syndrome Management.
@nl
prefLabel
Troponin concentrations for st ...... Ischemic Syndrome Management.
@en
Troponin concentrations for st ...... Ischemic Syndrome Management.
@nl
P2093
P1433
P1476
Troponin concentrations for st ...... Ischemic Syndrome Management.
@en
P2093
P304
P356
10.1016/S0140-6736(99)10285-X
P407
P577
1999-11-01T00:00:00Z